

## **Is vitamin D deficiency associated with the COVID-19 epidemic in Europe?**

Dimitra Rafailia Bakaloudi<sup>1</sup>, Michail Chourdakis<sup>1</sup>

<sup>1</sup> Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece.

**Corresponding Author:** Michail Chourdakis, Department of Medicine, School of Health Sciences, Aristotle University, University Campus, 54124, Thessaloniki, Greece; Phone: +30 2310 999035, Fax: +30 2312 205270;  
Email: [mhourd@gapps.auth.gr](mailto:mhourd@gapps.auth.gr)

**Short title:** Vitamin D and COVID-19 in Europe

**Acknowledgements:** We would like to most cordially thank Prof. Ranil Jayawardena and Dr. Dhanushya T Jeyakumar for their important contribution in all stages of the manuscript preparation.

**Financial Support:** This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

**Conflict of Interest:** None.

**Authorship:** Conceptualization and methodology, data collection, validation and analysis, writing-Original draft, review and editing: DB, MC

1 **Abstract**

2 Objective: COVID-19 has emerged as a global pandemic, affecting nearly 80 million people from  
3 218 countries as of December 2020. At the same time, vitamin D deficiency seems to be prevalent  
4 among COVID-19 patients. Hence, the association between the prevalence of vitamin D deficiency  
5 and COVID-19 infection and mortality among European countries was examined.

6 Design: A case series and recent literature review study

7 Settings: Information on prevalence of vitamin D deficiency in each country was retrieved through  
8 literature searching on PubMed® database. As of December, 23<sup>rd</sup> 2020, COVID-19 infections and  
9 mortalities per million population were extracted from the Worldometer website, whereas the latitude  
10 of each country was taken from the CSGNetwork website. The association between both vitamin D  
11 deficiency and COVID-19 infection and mortality were explored using correlation coefficients and  
12 scatterplots.

13 Participants: European Countries-Populations

14 Results: The range of prevalence of vitamin D deficiency among European countries was 6.9-75.1%,  
15 with most countries facing more than 50% of vitamin D deficiency among their population.  
16 Significant positive correlations were observed between COVID-19 infections ( $r=0.82$ ;  $p<0.001$ ) and  
17 mortalities ( $r=0.53$ ;  $p=0.05$ ) per million population with the prevalence of vitamin D deficiency. Most  
18 of the high latitude countries showed lower rates of COVID-19 infections and mortalities compared  
19 to middle latitude countries.

20 Conclusion: Prevalence of vitamin D deficiency was significantly associated with both infection and  
21 mortality rate of COVID-19 among European countries. Thus, it is an important parameter to be  
22 considered when implementing preventive measures to mitigate the mortality rate of COVID-19.

23

24 **Keywords:** Vitamin D, deficiency, COVID-19, infections, mortalities, Europe.

## 25 Introduction

26 COVID-19 has become a global public health emergency, affecting more than 80 million  
27 people from 218 countries and territories<sup>(1)</sup> in less than a year since the very first outbreak in Wuhan,  
28 China<sup>(2)</sup>. As of December, 23<sup>rd</sup> 2020, the lowest and highest number of confirmed cases per one  
29 million (1M) population, were reported among Oceanic (1380/1M) and North American (36,276/1M)  
30 continents respectively<sup>(3)</sup>. This substantial variation in the number of infections and as well as the  
31 severity and mortality of the disease can be accredited to several factors both at the state level as well  
32 as at an individual level. “State level” parameters include diverse factors, such as a country’s  
33 preparedness, actions of the governments, health infrastructure, timing of lockdown, rapid border  
34 closures, implementation of social distancing and socioeconomic status<sup>(4)</sup>, while the “individual  
35 level” includes the sociodemographic factors and other determinants of health status such as sex, age,  
36 chronic diseases, obesity, and malnutrition<sup>(5, 6)</sup>.

37 It is well known that malnutrition constitutes a risk factor for increased mortality and  
38 morbidity of several diseases<sup>(7)</sup>. Protein and energy malnutrition, and other specific micronutrient  
39 deficiencies have been shown to manifest adverse effects in immunity and thereby exhibit poor  
40 prognosis of viral infections<sup>(8)</sup>. Regarding micronutrients, the association between vitamin D (Vit D)  
41 deficiency and various diseases’ prevalence and/or severity, such as autoimmune disorders, diabetes  
42 and skeletal diseases have been adequately established in the past years<sup>(9)</sup>. However, there is limited  
43 evidence with regards to Vit D concentration and preventive and/or curative mechanisms of SARS-  
44 CoV-2 infection<sup>(10)</sup>. Recent studies have demonstrated the mechanisms for some possible interactions  
45 of serum vitamin D level with COVID-19 infections. Particularly, Vit D modulates the expression of  
46 angiotensin-converting enzyme 2 (ACE2), angiotensin (1-7) (Ang (1-7)) and mas receptor (MasR)  
47 axis and plays a crucial role in the protection against lung infection<sup>(11, 12)</sup>. Thereby it acts as a renin-  
48 angiotensin system (RAS) inhibitor in treating COVID-19 patients with underlying comorbidities<sup>(13,</sup>  
49 <sup>14)</sup>, and can lead to a weakening of the cytokine storm and the Acute Respiratory Syndrome (ARS)  
50 risk among COVID-19 patients<sup>(15, 16)</sup>. Moreover, Vit D is capable of exerting immunomodulatory  
51 function and improving mucosal defensive mechanisms and therefore an adequate serum  
52 concentration is more likely to be linked to a reduced mortality from respiratory diseases, such as  
53 COVID-19<sup>(17, 18)</sup>.

54 In Italy, COVID-19 patients admitted to a Respiratory Intermediate Care Unit (RICU) with  
55 severe Vit D deficiency (<10 ng/ml), showed a ten-fold mortality rate compared to those with a serum  
56 Vit D concentration >10 ng/ml ( $p < 0.05$ )<sup>(15)</sup>. Similarly, in a prospective observational study of  
57 critically ill patients treated in a multidisciplinary Intensive Care Unit (ICU), it was revealed that all  
58 patients who died within 28 days, belonged to the low Vit D group<sup>(19)</sup>. Munshi et al. also found that

59 COVID-19 patients with poor prognosis had significantly lower serum concentrations of Vit D  
60 ( $p < 0.001$ )<sup>(20)</sup>.

61 It is evident that Vit D deficiency could be associated with the severity and mortality of  
62 COVID-19. Hence, the aim of this study was to investigate the relationship between country-specific  
63 prevalence of Vit D deficiency with regards to infection and mortality rates of COVID-19 among  
64 European countries, given the fewer variations in terms of biological, social and economic factors,  
65 including health care facilities.

## 67 **Methods**

### 68 *Data sources and inclusion/exclusion criteria*

69 Information on COVID-19 infections and mortalities, were retrieved from the Worldometer  
70 website, which provides real time statistics<sup>(1)</sup>. This source contains data derived directly from official  
71 government reports of individual countries and/or indirectly through reliable local media resources.  
72 In addition, the latitude of each country was recorded from the CSGNetwork website, a reliable open  
73 source for the reference of close latitudes and longitudes of countries in the world<sup>(21)</sup>.

74 Data on the prevalence of Vit D deficiency among these countries were extracted by  
75 conducting a comprehensive electronic search in PubMed<sup>®</sup> database. An advanced search was  
76 performed at the level of title/abstract by using keywords such as “Vitamin D” or “25-hydroxyvitamin  
77 D<sub>3</sub>”, combined with “deficiency”, “prevalence” or “status” and the name of each European country.  
78 The final search string and additional information about the search strategy are presented in  
79 **Supplementary Table 1**. The search was limited to articles published in the last five years (up to  
80 December, 23<sup>rd</sup> 2020) and included data only for adult population (>19 years). Following inclusion  
81 criteria were applied for the screening of found articles: a) Population-based studies; b) studies  
82 reporting non-institutional adults; c) studies defining Vit D deficiency as the serum concentration <20  
83 ng/ml or <50 nmol/l; d) studies reporting Vit D deficiency as the prevalence of the sample population.  
84 In addition, conference proceedings, editorials, commentaries, book chapters/book reviews and  
85 studies confined to selective sample of community-dwelling people, such as pregnant women, elderly  
86 people, and patients with diagnosed illnesses were excluded. Finally, out of the screened articles for  
87 each country, the prevalence of Vit D deficiency data was retrieved from the most recently published  
88 study, including the most representative sample for each country.

### 90 *Data extraction*

91 For each European country, information on both COVID-19 infections and mortalities per 1M  
92 population as of December, 23<sup>rd</sup> 2020, were extracted from the Worldometer website<sup>(1)</sup> and the  
93 latitude was recorded from the CSGNetwork website<sup>(22)</sup>. From the selected articles reporting Vit D

94 deficiency among these countries, name of the first author, published year, sample size, age range of  
95 the study population and prevalence of Vit D deficiency were retrieved. All data were extracted by  
96 one reviewer (DB) using a standardized form and were checked for accuracy by a second reviewer  
97 (MC). Discrepancies in the extracted data were resolved by consensus.

98

### 99 *Data analysis*

100 The relationship between the prevalence of Vit D deficiency and other dependent variables,  
101 such as total number of COVID-19 infections and mortalities per 1M population were explored with  
102 correlation coefficients. Scatter plots were used to visually represent the correlations and the  
103 outcomes were evaluated by drawing a regression line. In the scatter plots, countries were  
104 differentiated according to their latitude following as; high latitude countries (50°N - 65°N) and  
105 middle latitude countries (35°N - 50°N). All countries were represented by a 3-letter country code  
106 according to the ISO (International Organization for Standardization) 3166, as per the Terminology  
107 Bulletin Country Names and the Country and Region Codes for Statistical Use maintained by the  
108 United Nations Statistics Divisions<sup>(23)</sup>.

109

### 110 **Results**

111 A total of 14 European countries, satisfying the inclusion/exclusion criteria were selected for  
112 the analysis<sup>(24-37)</sup> (**Table 1**). The prevalence of Vit D deficiency ranged from 6.9-75.1% with the  
113 lowest and highest rates reported in Finland and France respectively. In more than half of the  
114 countries, the majority of the adult population was Vit D deficient (i.e. <20 ng/ml or <50 nmol/l). The  
115 size of study population which was used to retrieve data for the prevalence of Vit D deficiency varied  
116 from 222 (United Kingdom) to 74,235 subjects (Italy). As of December, 23<sup>rd</sup> 2020, in regard to the  
117 total number of COVID-19 infections per 1M of the total population, Finland reported the lowest  
118 with 6,147/1M, while France had the highest with 38,350/1M infections. In regard to the COVID-19  
119 mortalities per 1M population, the lowest number, was documented in Norway (77 deaths/1M),  
120 whereas the highest number, was reported in Bosnia and Herzegovina (1,173 deaths/1M).

121 Cases of COVID-19 infections per 1M population displayed a significant, strong positive  
122 correlation ( $r=0.82$ ;  $p<0.001$ ) with the prevalence of Vit D deficiency (**Figure 1**). Moreover, a 67%  
123 of the variation ( $R^2=0.67$ ) in total infections was attributed to the high prevalence of Vit D deficiency.  
124 In addition, a sharp upward trend was observed by the regression line resulted from the correlation  
125 analysis and most countries were scattered around the line, with Italy as the single outlier. The  
126 correlation effect noticeably improved to 0.90 after removing the outlier (Italy) from the analysis  
127 ( $r=0.90$ ;  $p<0.001$ ;  $R^2=0.81$ ).

128 Among the included European countries, the bottom and the top ends of the regression line  
129 were occupied by Finland, a high latitude country (50°N - 65°N) and France, a middle latitude country  
130 (35°N - 50°N) respectively, corresponding to the lowest and highest values for both the prevalence of  
131 Vit D deficiency and the number of COVID-19 infections per 1M population. High latitude countries  
132 showed greater variation in the prevalence of Vit D deficiency as well as in the number of COVID-  
133 19 infections. Particularly, the lower end was surrounded mostly by high latitude countries such as  
134 Finland, Norway and Ireland, indicating low prevalence of Vit D deficiency and low infection rate.  
135 Furthermore, other high latitude countries such as Russia, Denmark and Germany were clustered  
136 below the upper middle of the regression line with moderate prevalence of Vit D deficiency and  
137 moderate infection rate (Figure 1). However, all the middle latitude countries, except Greece, were  
138 located around the top end of the regression line, with higher values for both prevalence of Vit D  
139 deficiency and number of COVID-19 infections. In contrast, only two out of six high latitude  
140 countries (United Kingdom and Poland) were positioned around the top end of the regression line.

141 As illustrated in **Figure 2**, COVID-19 mortality per 1M population was also significantly  
142 positively correlated with the prevalence of Vit D deficiency ( $r=0.53$ ;  $p=0.05$ ). Most of the countries  
143 were scattered around the regression line, indicating 28% variability ( $R^2=0.28$ ) among the mortalities  
144 being due to the high prevalence of Vit D deficiency. Similarly to Figure 1, Italy was positioned as  
145 the outlier, and the correlation was increased markedly when it was removed from the analysis  
146 ( $r=0.70$ ;  $p<0.001$ ;  $R^2=0.48$ ). All the high latitude countries except United Kingdom, Poland and  
147 Germany, were located below the midpoint of the regression line, indicating the lower prevalence of  
148 Vit D deficiency and COVID-19 mortalities. On the contrary, all middle latitude countries, except  
149 Greece and Denmark, were found to be clustered around the top end of the line, denoting higher levels  
150 for both variables. Notably, in countries such as Denmark and Germany, moderate levels of mortality  
151 were observed, despite the higher levels of Vit D deficiency.

152

## 153 Discussion

154 Our analysis concluded that the prevalence of Vit D deficiency among the European  
155 population can be a potential risk factor for both COVID-19 infection and mortality rates. These  
156 findings are compatible with the outcomes of prior research works<sup>(38-40)</sup>.

157 According to the outcomes of our study, in most of the European countries included in this  
158 analysis, more than 50% of the adult population was Vit D deficient, which constitutes an important  
159 factor to consider in the planning of public health preventive measures. One of the main reasons for  
160 the high prevalence of Vit D deficiency could be the urban lifestyle of the people residing in these  
161 countries<sup>(41)</sup>. Additionally, the fluctuations of sunlight exposure among seasons could also impact  
162 the proportion of Vit D deficient population<sup>(42)</sup>. Especially the negligible amount of sunlight during



163 winter and cloud covers during summer could potentially reduce the cutaneous synthesis of Vit D in  
164 some less south located countries<sup>(41, 43)</sup>. Furthermore, dietary sources of Vit D are limited and the  
165 obesity epidemic in the Europe, which is also related to poorer dietary choices, has worsened its  
166 deficiency<sup>(44)</sup>.

167 The results of our analysis showed that most of the high latitude European countries (50°N -  
168 65°N) had lower levels of infection and mortality rates, comparatively to the middle latitude ones  
169 (35°N - 50°N). This indicates that the latitude of these countries does not impact the prevalence of  
170 Vit D deficiency among their population. This result is in accordance with the findings of a study  
171 conducted in Honolulu, Hawaii (latitude of 21°N), where 51% of the population reported lower serum  
172 concentrations of Vit D, despite the theoretically sufficient UV exposure<sup>(45)</sup>. Consequently, dietary  
173 intake of Vit D is considered to be the crucial factor related to the prevalence of Vit D deficiency  
174 among these European countries<sup>(46)</sup>. However, adequate serum concentrations of Vit D cannot be  
175 easily reached only by dietary sources<sup>(47)</sup>. Therefore, Vit D concentration improvement among the  
176 population of these countries should be targeted for as per the food fortification guidelines by the  
177 European Calcified Tissue Society (ECTS); at the same time enough attention should be paid to the  
178 monitoring of quality assurance in order to prevent intoxication<sup>(48)</sup>.

179 Moreover, a similar pattern regarding the positions of the countries in the scatter plots of both  
180 COVID-19 infection and mortality rates against the prevalence of Vit D deficiency was observed.  
181 Italy was the single outlier in both scatter plots. This could be possible since it was one of the highly  
182 affected countries with serious clusters, soon after the breakout of COVID-19 pandemic<sup>(49)</sup>, but later  
183 on both infection and mortality rates were reduced due to new treatment modalities<sup>(50)</sup>. In addition,  
184 the position of Greece on the scatter plots was below the middle of the regression line, representing  
185 the moderate rates of COVID-19 infection and mortality, although the prevalence of Vit D deficiency  
186 was similar to Italy. The Greek government tried to confront the pandemic by acting at early stages  
187 through implementing a strict lockdown and also via effective communication with the public,  
188 especially in the context of the predominance of an elderly population and despite the fragile  
189 economy<sup>(51)</sup>.

190 Differences between the plots were observed only for two countries, in particular Germany  
191 and Denmark. These two countries were found to have a relatively lower number of COVID-19  
192 mortalities, despite of the moderate infection rates and the fact that more than 50% of their population  
193 presented Vit D deficiency. This outcome could be explained by several factors, such as advanced  
194 preventive and curative health policies, strict border closures, swift actions of the government and  
195 more importantly, by the early and adequate screening of COVID-19 among their population<sup>(52)</sup>.  
196 Especially in Denmark up to 1,692,090 PCR tests/1M were performed, as of December, 23<sup>rd</sup> 2020<sup>(1)</sup>.

197 Although only 14 European countries satisfied our inclusion criteria, the analysis included  
198 nearly 64% of the entire European population<sup>(3)</sup>. Therefore, the results of our study can be generalized  
199 to most of the excluded European countries as well. Moreover, along with the majority of high income  
200 countries, upper-middle income countries, such as Russia and Bosnia and Herzegovina were also  
201 included in the analysis<sup>(53)</sup>, reflecting the effect of economic status in the outcomes. However, most  
202 of the data on prevalence of Vit D deficiency among these countries were not generated from national  
203 level surveys. Therefore, the very recently published studies with most representative sample of each  
204 country population were carefully selected for the analysis. The screened studies were limited to  
205 adults (>19 years), as the severity of COVID-19 infections among children was mild<sup>(54)</sup>, but one study  
206 included population of 16 years old as well<sup>(33)</sup>. Furthermore, the overall prevalence of Vit D  
207 deficiency of the adult population was considered, even though there were considerable variations in  
208 the prevalence among different age groups. Similarly, the mean prevalence of Vit D deficiency was  
209 considered when different prevalence values were reported among various seasons. In addition,  
210 obesity constitutes a confounder of Vit D deficiency, COVID-19 infections and as well as mortalities,  
211 but in the outcomes of our study the effects of obesity in both variables were not reflected<sup>(55)</sup>.

212 Governments should implement proper preventive measures to increase awareness among the  
213 populations on the risk of Vit D deficiency and on its role in severity and mortality of the COVID-19  
214 pandemic. People should be encouraged to increase their dietary intake of Vit D, in addition to  
215 achieving adequate sunlight exposure. A preferred strategy could be Vit D fortification of foods with  
216 the intention to reduce the prevalence of Vit D deficiency. In addition, Vit D supplementation should  
217 be advised for those belonging to a high risk group of deficiency, such as new-borns, toddlers,  
218 pregnant women, elderly as well as non-Western immigrants<sup>(48)</sup>. Moreover, regular country-wise  
219 assessment of Vit D status with standardized 25 (OH)D questionnaires should be encouraged as they  
220 can provide insights into future intervention therapies of diseases, such as COVID-19<sup>(56)</sup>.

221

## 222 **Conclusions**

223 Significant positive correlations were detected between the total number of COVID-19  
224 infections per 1M population ( $r=0.82$ ;  $p<0.001$ ) and mortality per 1M population ( $r=0.53$ ;  $p=0.05$ )  
225 with respect to country-specific prevalence of Vit D deficiency among 14 European countries. Most  
226 of the high latitude European countries showed less values for both COVID-19 infection and  
227 mortality rates, while most of middle latitude countries showed higher values for both variables.  
228 Germany and Denmark had lower mortality rates despite moderate levels of COVID-19 infections  
229 and prevalence of Vit D deficiency, due to swift government actions, strict border closures and high  
230 level of testing.

231



232 **Abbreviations**

233

234 **1M:** One million; **25(OH)D:** 25-hydroxyvitamin D<sub>3</sub>; **ACE2:** Angiotensin-Converting Enzyme 2;  
235 **Ang (1-7):** Angiotensin (1-7); **ARS:** Acute Respiratory Syndrome; **COVID-19:** Coronavirus disease  
236 2019; **ECTS:** European Calcified Tissue Society; **ICU:** Intensive Care Unit; **ISO:** International  
237 Organization for Standardization; **MasR:** Mas Receptor; **PCR:** Polymerase Chain Reaction; **RAS:**  
238 Renin - Angiotensin System; **RICU:** Respiratory Intermediate Care Unit; **SARS-CoV-2:** Severe  
239 Acute Respiratory Syndrome Coronavirus; **UV:** Ultraviolet; **UVB:** Ultraviolet B; **Vit D:** Vitamin D.

WITHDRAWN  
see manuscript DOI for details

## 240 **References**

241

- 242 1. (2020) Worldometer, COVID-19 Coronavirus Pandemic  
243 <https://www.worldometers.info/coronavirus/> (accessed 24 Dec 2020 2020)
- 244 2. Zhu H, Wei L Niu P (2020) The novel coronavirus outbreak in Wuhan, China. *Global health research*  
245 *and policy* 5, 1-3.
- 246 3. (2020) WHO Coronavirus Disease (COVID-19) Dashboard. *Situation by WHO Region*.  
247 <https://covid19.who.int/> (accessed 24 December 2020)
- 248 4. Chaudhry R, Dranitsaris G, Mubashir T *et al.* (2020) A country level analysis measuring the impact of  
249 government actions, country preparedness and socioeconomic factors on COVID-19 mortality and  
250 related health outcomes. *EClinicalMedicine* 25, 100464.
- 251 5. Fedele D, De Francesco A, Riso S *et al.* (2020) Obesity, malnutrition, and trace element deficiency in  
252 the coronavirus disease (COVID-19) pandemic: An overview. *Nutrition (Burbank, Los Angeles*  
253 *County, Calif)* 81, 111016-111016.
- 254 6. Clark A, Jit M, Warren-Gash C *et al.* (2020) Global, regional, and national estimates of the  
255 population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a  
256 modelling study. *The Lancet Global Health* 8, e1003-e1017.
- 257 7. Söderström L, Rosenblad A, Adolfsson ET *et al.* (2017) Malnutrition is associated with increased  
258 mortality in older adults regardless of the cause of death. *British Journal of Nutrition* 117, 532-540.
- 259 8. Jayawardena R, Sooriyaarachchi P, Chourdakis M *et al.* (2020) Enhancing immunity in viral  
260 infections, with special emphasis on COVID-19: A review. *Diabetes & Metabolic Syndrome: Clinical*  
261 *Research & Reviews*.
- 262 9. Wacker M & Holick MF (2013) Vitamin D—effects on skeletal and extraskelatal health and the need  
263 for supplementation. *Nutrients* 5, 111-148.
- 264 10. Ali N (2020) Role of vitamin D in preventing of COVID-19 infection, progression and severity. *Journal*  
265 *of infection and public health*.
- 266 11. Cui C, Xu P, Li G *et al.* (2019) Vitamin D receptor activation regulates microglia polarization and  
267 oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: role  
268 of renin-angiotensin system. *Redox biology* 26, 101295.
- 269 12. Li Y, Zeng Z, Cao Y *et al.* (2016) Angiotensin-converting enzyme 2 prevents lipopolysaccharide-  
270 induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways. *Scientific*  
271 *reports* 6, 27911.
- 272 13. Kuster GM, Pfister O, Burkard T *et al.* (2020) SARS-CoV2: should inhibitors of the renin–angiotensin  
273 system be withdrawn in patients with COVID-19? *European Heart Journal*.
- 274 14. Li YC, Qiao G, Uskokovic M *et al.* (2004) Vitamin D: a negative endocrine regulator of the renin–  
275 angiotensin system and blood pressure. *The Journal of steroid biochemistry and molecular biology*  
276 89, 387-392.
- 277 15. Carpagnano GE, Di Lecce V, Quaranta VN *et al.* (2020) Vitamin D deficiency as a predictor of poor  
278 prognosis in patients with acute respiratory failure due to COVID-19. *Journal of endocrinological*  
279 *investigation*, 1-7.
- 280 16. Daneshkhah A, Agrawal V, Eshein A *et al.* (2020) Evidence for possible association of vitamin D  
281 status with cytokine storm and unregulated inflammation in COVID-19 patients. *Aging Clinical and*  
282 *Experimental Research* 32, 2141-2158.
- 283 17. Baeke F, Takiishi T, Korf H *et al.* (2010) Vitamin D: modulator of the immune system. *Current*  
284 *opinion in pharmacology* 10, 482-496.
- 285 18. Barlow PG, Beaumont PE, Cosseau C *et al.* (2010) The human cathelicidin LL-37 preferentially  
286 promotes apoptosis of infected airway epithelium. *American journal of respiratory cell and*  
287 *molecular biology* 43, 692-702.
- 288 19. Vassiliou AG, Jahaj E, Pratikaki M *et al.* (2020) Low 25-Hydroxyvitamin D Levels on Admission to the  
289 Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality  
290 Risk: A Pilot Study on a Greek ICU Cohort. *Nutrients* 12, 3773.

- 291 20. Munshi R, Hussein MH, Toraih EA *et al.* (2020) Vitamin D insufficiency as a potential culprit in  
292 critical COVID-19 patients. *Journal of medical virology*.
- 293 21. Haywood LJ, Khan AH, Bornheimer J *et al.* (1997) Recurrent myocardial infarction with patent  
294 coronary arteries. *Journal of the National Medical Association* 89, 415-420.
- 295 22. Ulmer HE, Knapp WH, Schärer K (1975) EXERCISE TESTS AND ECHOCARDIOGRAPHY IN CHILDREN  
296 WITH CHRONIC RENAL-FAILURE -CRF. *Pediatric Research* 9, 855.
- 297 23. Cade P (1997) How exercise can change "disability" to "ability" in the ESRD patient. *Nephrology*  
298 *news & issues* 11, 55-56.
- 299 24. Sokolovic S, Alimanovic-Alagic R, Džananovic L *et al.* (2017) Vitamin D status in Bosnia and  
300 Herzegovina: the cross-sectional epidemiological analysis. *Osteoporos Int* 28, 1021-1025.
- 301 25. Hansen L, Tjønneland A, Køster B *et al.* (2018) Vitamin D Status and Seasonal Variation among  
302 Danish Children and Adults: A Descriptive Study. *Nutrients* 10.
- 303 26. Adebayo FA, Ikonen ST, Lilja E *et al.* (2020) Prevalence and determinants of vitamin D deficiency  
304 and insufficiency among three immigrant groups in Finland: evidence from a population-based  
305 study using standardised 25-hydroxyvitamin D data. *Public Health Nutr* 23, 1254-1265.
- 306 27. Deplanque X, Wullens A, Norberciak L (2017) [Prevalence and risk factors of vitamin D deficiency in  
307 healthy adults aged 18-65 years in northern France]. *Rev Med Interne* 38, 368-373.
- 308 28. Rabenberg M, Scheidt-Nave C, Busch MA *et al.* (2018) Implications of standardization of serum 25-  
309 hydroxyvitamin D data for the evaluation of vitamin D status in Germany, including a temporal  
310 analysis. *BMC Public Health* 18, 845.
- 311 29. Dimakopoulos I, Magriplis E, Mitsopoulou AV *et al.* (2019) Association of serum vitamin D status  
312 with dietary intake and sun exposure in adults. *Clin Nutr ESPEN* 34, 23-31.
- 313 30. Griffin TP, Wall D, Blake L *et al.* (2020) Higher risk of vitamin D insufficiency/deficiency for rural  
314 than urban dwellers. *The Journal of Steroid Biochemistry and Molecular Biology* 197, 105547.
- 315 31. Giuliani S, Barbieri V, Di Piero AM *et al.* (2019) LC-MS/MS based 25(OH)D status in a large Southern  
316 European outpatient cohort: gender- and age-specific differences. *Eur J Nutr* 58, 2511-2520.
- 317 32. Petrenya N, Lamberg-Allardt C, Melhus M *et al.* (2020) Vitamin D status in a multi-ethnic population  
318 of northern Norway: the SAMINOR 2 Clinical Survey. *Public Health Nutr* 23, 1186-1200.
- 319 33. Płudowski P, Ducki C, Konstantynowicz J *et al.* (2016) Vitamin D status in Poland. *Pol Arch Med*  
320 *Wewn* 126, 530-539.
- 321 34. Duarte C, Carvalheiro H, Rodrigues AM *et al.* (2020) Prevalence of vitamin D deficiency and its  
322 predictors in the Portuguese population: a nationwide population-based study. *Arch Osteoporos*  
323 15, 36.
- 324 35. Niculescu DA, Capatina CAM, Dusceac R *et al.* (2017) Seasonal variation of serum vitamin D levels in  
325 Romania. *Arch Osteoporos* 12, 113.
- 326 36. Karonova T, Andreeva A, Nikitina I *et al.* (2016) Prevalence of Vitamin D deficiency in the North-  
327 West region of Russia: A cross-sectional study. *J Steroid Biochem Mol Biol* 164, 230-234.
- 328 37. Jolliffe DA, Hanifa Y, Witt KD *et al.* (2016) Environmental and genetic determinants of vitamin D  
329 status among older adults in London, UK. *J Steroid Biochem Mol Biol* 164, 30-35.
- 330 38. De Smet D, De Smet K, Herroelen P *et al.* (2020) Vitamin D deficiency as risk factor for severe  
331 COVID-19: a convergence of two pandemics. *MedRxiv*.
- 332 39. Laird E, Rhodes J, Kenny RA (2020) Vitamin D and inflammation: potential implications for severity  
333 of Covid-19. *Ir Med J* 113, 81.
- 334 40. Radujkovic A, Hippchen T, Tiwari-Heckler S *et al.* (2020) Vitamin D deficiency and outcome of  
335 COVID-19 patients. *Nutrients* 12, 2757.
- 336 41. Mendes MM, Darling AL, Hart KH *et al.* (2019) Impact of high latitude, urban living and ethnicity on  
337 25-hydroxyvitamin D status: A need for multidisciplinary action? *The Journal of Steroid Biochemistry*  
338 *and Molecular Biology* 188, 95-102.
- 339 42. Schramm S, Lahner H, Jöckel K-H *et al.* (2017) Impact of season and different vitamin D thresholds  
340 on prevalence of vitamin D deficiency in epidemiological cohorts—a note of caution. *Endocrine* 56,  
341 658-666.
- 342 43. Webb A, Kift R, Durkin M *et al.* (2010) The role of sunlight exposure in determining the vitamin D  
343 status of the UK white adult population. *British Journal of Dermatology* 163, 1050-1055.

- 344 44. Snijder MB, van Dam RM, Visser M *et al.* (2005) Adiposity in relation to vitamin D status and  
345 parathyroid hormone levels: a population-based study in older men and women. *The Journal of*  
346 *Clinical Endocrinology & Metabolism* 90, 4119-4123.
- 347 45. Binkley N, Novotny R, Krueger D *et al.* (2007) Low vitamin D status despite abundant sun exposure.  
348 *The Journal of Clinical Endocrinology & Metabolism* 92, 2130-2135.
- 349 46. van Schoor N & Lips P (2018) Worldwide vitamin D status. In *Vitamin D*, pp. 15-40: Elsevier.
- 350 47. Kasapidou E, Oikonomidou A Chourdakis M (2018) Vitamin D status among Mediterranean regions.  
351 *Hippokratia* 22, 191.
- 352 48. Lips P, Cashman KD, Lamberg-Allardt C *et al.* (2019) Current vitamin D status in European and  
353 Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the  
354 European Calcified Tissue Society. *European Journal of Endocrinology* 180, P23-P54.
- 355 49. Livingston E & Bucher K (2020) Coronavirus disease 2019 (COVID-19) in Italy. *Jama* 323, 1335-1335.
- 356 50. Drożdżal S, Rosik J, Lechowicz K *et al.* (2020) FDA approved drugs with pharmacotherapeutic  
357 potential for SARS-CoV-2 (COVID-19) therapy. *Drug resistance updates*, 100719.
- 358 51. Perrigo B & Hincks J (2020) Greece has an Elderly Population and a Fragile Economy. How Has it  
359 Escaped the Worst of the Coronavirus so Far?: Time. Disponible en: <https://time.com/5824836/greece-coronavirus>.
- 360
- 361 52. Stafford N (2020) Covid-19: Why Germany's case fatality rate seems so low. *Bmj* 369.
- 362 53. Ono M (1979) Exercise Capacity of Children with Chronic Renal Failure (Part 3) (Permissible exercise  
363 strength the patients). *Japanese Journal of Nephrology* 21, 1105-1111.
- 364 54. Brodin P (2020) Why is COVID-19 so mild in children? *Acta Paediatrica* 109, 1082-1083.
- 365 55. Jayawardena R, Jeyakumar DT, Misra A *et al.* (2020) Obesity: A potential risk factor for infection and  
366 mortality in the current COVID-19 epidemic. *Diabetes & Metabolic Syndrome: Clinical Research &*  
367 *Reviews* 14, 2199-2203.
- 368 56. Castillo ME, Costa LME, Barrios JM *et al.* (2020) Effect of calcifediol treatment and best available  
369 therapy versus best available therapy on intensive care unit admission and mortality among  
370 patients hospitalized for COVID-19: A pilot randomized clinical study. *The Journal of steroid*  
371 *biochemistry and molecular biology* 203, 105751.

373 **Figure Legends**

374

375 **Figure 1:** Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 infections,  
376 as of December, 23<sup>rd</sup> 2020.

377 **Figure 2:** Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 mortalities,  
378 as of December, 23<sup>rd</sup> 2020.


WITHDRAWN  
see manuscript DOI for details

379 **Table 1:** The prevalence of vitamin D deficiency among 14 European countries.

Country	Author, Year	Sample size (M/ F)	Age (years)	Prevalence of vitamin D deficiency* (%)
Bosnia and Herzegovina <sup>(24)</sup>	Sokolovic et al., 2016	2483 (603/1880)	>18	58.7
Denmark <sup>(25)</sup>	Hansen et al., 2018	2565 (1048/1517)	18-69	51.5
Finland <sup>(26)</sup>	Adebayo et al., 2020	798 (NA)	30-64	6.9
France <sup>(27)</sup>	Deplanque et al., 2017	297 (NA)	18-65	75.1
Germany <sup>(28)</sup>	Rabenberg et al., 2018	6995 (3360/3635)	18-79	61.5
Greece <sup>(29)</sup>	Dimakopoulos et al., 2019	1084 (410/674)	≥18	32.4
Ireland <sup>(30)</sup>	Griffin et al., 2020	17590 (NA)	>18	19.5
Italy <sup>(31)</sup>	Giuliani et al., 2018	74235 (18811/55424)	>18	33.3
Norway <sup>(32)</sup>	Petrenya et al., 2020	4465 (2041/2424)	40-69	24.7
Poland <sup>(33)</sup>	Pludowski et al., 2016	5775 (1311/4464)	16-90	65.8
Portugal <sup>(34)</sup>	Duarte et al., 2020	3092 (1907/1995)	≥18	66.6
Romania <sup>(35)</sup>	Niculescu et al., 2017	812 (NA)	>21	56.5
Russia <sup>(36)</sup>	Karonova et al., 2016	1544 (205/1294)	18-75	45.7
United Kingdom <sup>(37)</sup>	Jolliffe et al., 2016	222 (89/133)	48-94	64.9

380 F, female; M, male; NA, not available, \*Serum 25-hydroxyvitamin D<sub>3</sub> concentration <20 ng/ml or <50 nmol/l.






**Figure 1:** Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 infections, as of December, 23<sup>rd</sup> 2020.

BIH: Bosnia and Herzegovina; DEU: Germany; DNK: Denmark; FIN: Finland; FRA: France; GBR: United Kingdom; GRC: Greece; IRE: Ireland; ITA: Italy; NOR: Norway; POL: Poland; PRT: Portugal; ROU: Romania; RUS: Russia.

▲ - High latitude countries (50°N - 65°N); ● - Middle latitude countries (35°N - 50°N).



**Figure 1:** Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 mortalities, as of December, 23<sup>rd</sup> 2020.

BIH: Bosnia and Herzegovina; DEU: Germany; DNK: Denmark; FIN: Finland; FRA: France; GBR: United Kingdom; GRC: Greece; IRE: Ireland; ITA: Italy; NOR: Norway; POL: Poland; PRT: Portugal; ROU: Romania; RUS: Russia.

▲ - High latitude countries (50°N - 65°N); ● - Middle latitude countries (35°N - 50°N).